Viz.ai gets FDA De Novo approval for AI-enabled heart disease detection

The U.S. Food and Drug Administration’s approval of Viz.ai’s hypertrophic cardiomyopathy establishes a new category for cardiovascular machine learning-based notification software.
WHY IT MATTERS
Viz.ai, a disease detection and intelligent care coordination company, said in its announcement…

Source: Healthcareitnews.com and Read More